未名医药: 关于涉及诉讼事项的进展公告

Group 1 - The company's retrial application was rejected, and it has fully accrued estimated liabilities and losses based on the second-instance judgment, which will not negatively impact the company's current or future profits [1][3]. - The court ruled that the company must compensate for half of the amount owed to Shen Xiangxin, totaling 60,960,436.85 yuan, within ten days of the judgment taking effect [3]. - As of the announcement date, the company has no other undisclosed litigation or arbitration matters [3]. Group 2 - The company emphasizes the importance of accurate and complete information disclosure, ensuring that there are no false records or misleading statements [1][4]. - The company has designated a specific media outlet for information disclosure, and all information will be published through this channel [4].